Abstract | BACKGROUND: METHODS: The five products of breast carcinoma cells were measured in 184 patients with node-negative breast carcinoma who were enrolled in the Kumamoto Adjuvant Chemo-Endocrine Therapy for Breast Cancer prospective randomized trial, and the predictive values of these factors for relapse-free and overall survival were evaluated. RESULTS: M-PLA2, PMN-E, and t-PA were found to be significant independent predictors of relapse-free and overall survival, whereas u-PA and ET-1 were not independently predictive. Further statistical analyses showed that the predictive powers of M-PLA2, PMN-E, and t-PA were additive. A combination of these three factors identified a group of patients (approximately 50% of those who manifested node-negative breast carcinoma) with a favorable prognosis, regardless of the administration of adjuvant therapy. CONCLUSIONS:
|
Authors | J Yamashita, M Ogawa, K Sakai |
Journal | Surgery
(Surgery)
Vol. 117
Issue 6
Pg. 601-8
(Jun 1995)
ISSN: 0039-6060 [Print] United States |
PMID | 7778023
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Endothelins
- Tamoxifen
- Phospholipases A
- Phospholipases A2
- Pancreatic Elastase
- Leukocyte Elastase
- Tissue Plasminogen Activator
- Urokinase-Type Plasminogen Activator
|
Topics |
- Breast Neoplasms
(chemistry, drug therapy, pathology)
- Carcinoma
(chemistry, drug therapy, pathology)
- Chemotherapy, Adjuvant
- Disease-Free Survival
- Endothelins
(analysis)
- Female
- Follow-Up Studies
- Humans
- Leukocyte Elastase
- Mastectomy, Modified Radical
- Mastectomy, Radical
- Neoplasm Staging
- Pancreatic Elastase
(analysis)
- Phospholipases A
(analysis)
- Phospholipases A2
- Prognosis
- Prospective Studies
- Risk Factors
- Survival Rate
- Tamoxifen
(therapeutic use)
- Tissue Plasminogen Activator
(analysis)
- Urokinase-Type Plasminogen Activator
(analysis)
|